Effects of hyperbaric oxygen combined with radiochemotherapy on immune function in patients with breast cancer and its prognosis
10.3760/cma.j.cn311847-20200116-00027
- VernacularTitle:高压氧联合放化疗对乳腺癌患者免疫功能及预后的影响
- Author:
Dengfeng XUE
1
;
Ruihong HOU
;
Xiangyang GUO
;
Xinzheng LI
Author Information
1. 030001 太原，山西省肿瘤医院乳腺外科
- Publication Type:Journal Article
- Keywords:
Hyperbaric oxygen;
Radiochemotherapy;
Breast cancer;
Immune function;
Tumor recurrence
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2020;27(3):334-337
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effects of hyperbaric oxygen(HBO) combined with radiochemotherapy on the immune function and prognosis of patients with breast cancer.Methods:A total of 144 breast cancer patients admitted in the Department of Breast Surgery, Shanxi Provincial Cancer Hospital from June 2017 to December 2018 were selected as the research objects and randomly divided into control group ( n=72) and observation group ( n=72) according to random number table method. The control group was given the conventional radiochemotherapy treatment, and the observation group was treated with the hyperbaric oxygen (HBO) therapy on the basis of the treatment in the control group. The changes of the immunoglobulin (IgG and IgM) and their complements (C3 and C4), CD3 + , CD4 + , and CD8 + T lymphocytes of the two groups were compared before and after the treatment. The adverse reactions, complications, tumor recurrence and metastasis of the patients in the two groups were compared in a 1-year follow-up. Results:After 6 courses of the treatment, the immunoglobulin (IgG and IgM) and their complements (C3 and C4) levels of the patients in the observation group were significantly higher than those in the control group. The difference was statistically significant ( P<0.05). CD4 + T lymphocyte count was also obviously higher than that of the control group ( P<0.05). One-year follow-up showed that the bone marrow toxicity, gastrointestinal reaction, and hair loss of the patients in the observation group were significantly better than those in the control group, and the incidences of breast cancer recurrence and metastasis were significantly lower than those in the control group with statistically significant difference ( P<0.05 or P<0.01). Conclusion:HBO therapy, as an assisting treatment, can effectively enhance the immunity of breast cancer patients after radiochemotherapy, reduce the occurrence of adverse reactions, and delay tumor recurrence and metastasis.
